ALARIS MEDICAL SYSTEMS INC
10-Q/A, 2000-12-04
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Previous: LIFE FINANCIAL CORP, SC 13D/A, 2000-12-04
Next: ALARIS MEDICAL SYSTEMS INC, 10-Q/A, EX-10.21, 2000-12-04



<PAGE>


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
                                    FORM 10-Q/A



      (MARK ONE)
        |X|       Quarterly Report Pursuant to Section 13 or 15(d) of the
                  Securities Exchange Act of 1934

      For the quarterly period ended SEPTEMBER 30, 2000 or

        | |       Transition Report Pursuant to Section 13 or 15(d) of the
                  Securities Exchange Act of 1934

      For the transition period from ___________ to ___________


Commission File Number:                  333-18687
                       ----------------------------------------


                          ALARIS MEDICAL SYSTEMS, INC.
------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

   Delaware                                                 13-3800335
--------------------------------------       ---------------------------------
(State or other jurisdiction of                         (I.R.S. Employer
 incorporation or organization)                         Identification No.)

                   10221 Wateridge Circle, San Diego, CA 92121
------------------------------------------------------------------------------
     (Address of principal executive offices)                    (Zip Code)

                                 (858) 458-7000
------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

------------------------------------------------------------------------------
            (Former name, former address and former fiscal year, if
                           changed since last report)



Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes: X    No:
                                              ---       ---

On November 9, 2000, 1,000 shares of Registrant's Common Stock were outstanding.


The purpose of this form 10 Q/A is to amend Item 6 to add an exhibit as of
September 30, 2000.



                                Page 1 of 26
<PAGE>




ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

(a)   Exhibits


10.21     Amendment No. 7 and Consent to the Bank Credit Agreement dated as
          of August 28, 2000, among ALARIS Medical, Inc., ALARIS Medical
          Systems, Inc., the financial institutions party to the Credit
          Agreement, Bankers Trust Company and Banque Paribas.



27        --     Financial Data Schedule      (Previously filed)


                                  -----------------------------------------


(b)   Reports on Form 8-K

During the quarter ended September 30, 2000 the Company filed a report on Form
8-K dated September 15, 2000. This report contained information and pro forma
financial statements related to the sale of the Instromedix division to Card
Guard Technologies, Inc.


                                     -25-


<PAGE>







                                   SIGNATURES



        Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


                                                   ALARIS MEDICAL SYSTEMS, INC.
                                                   ---------------------------
                                                                  (REGISTRANT)


        Date:   December 4, 2000                By:      /s/ WILLIAM C. BOPP
                                                   ---------------------------
                                                               William C. Bopp
                                                   Senior Vice President and
                                                   Chief Financial Officer



                                     -26-



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission